Home
overview

The field of diabetes offers the pharmaceutical industry a constantly growing market with major potential. This unique conference will explore the latest therapeutic approaches. It will be informative, stimulating and focused.

As a senior industry executive, you will be aware of the importance and potential of this field. We would therefore like to invite you to register for SMi’s conference on Diabetes: Novel Therapeutic Developments. As you will see from the brochure, key speakers include representatives from leading international pharmaceutical and biotechnology companies.

The conference offers you the opportunity to network with key industry experts. Attend to discover the potential and realities of the anti-diabetics market, and to match your company’s resources to the needs of the patient.

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Prof Harry Keen

Prof Harry Keen, Co-Director, WHO Collaborating Centre for the Study and Control of Long-Term Complications of Diabetes Mellitus, Honorary President, International Diabetes Federation

9:10 MARKET OPPORTUNITIES WITHIN THE DIABETES FIELD

Liv Inga K Tonjum, Research Manager

Liv Inga K Tonjum, Research Manager, Jane Davidson, Marketing Manager Pharma, Frost and Sullivan

  • Rapid growth of the diabetes market
  • Growing prevalence of diabetes in emerging markets
  • Key factors driving the success of leading products
  • Analysis of R and D pipelines
  • Impact of new product launches on the diabetes market
  • Impact of disease management programmes on the diabetes market
  • 9:40 DISCUSSING FILING OPTIONS WITH REGULATORY AUTHORITIES

    Dr Orville G. Kolterman

    Dr Orville G. Kolterman, Senior Vice President, Clinical Affairs, Amylin Pharmaceuticals

  • Introducing pramlintide, a new diabetes drug candidate
  • Mechanism of action of pramlintide
  • Working out a regulatory filing strategy
  • Early identification of better responding patients
  • Durability of the drug effect
  • Gaining substantial benefit in terms of glucose control
  • 10:20 BAYER: CONTROLLING BLOOD GLUCOSE LEVELS

    Dr James Magner

    Dr James Magner, Deputy Director Metabolic Clinical Research, Bayer

  • The importance of postprandial hyperglycemia
  • Mechanism of action and experience with acarbose
  • Adding alpha-glucosidase inhibitors to other therapies
  • Acarbose in the UKPDS
  • 11:00 Morning Coffee

    11:20 FINDING NOVEL ANTI-DIABETICS

    Dr Anthony H Cincotta

    Dr Anthony H Cincotta, Chief Scientific Officer, Ergo Science

  • Improving insulin sensitivity in the treatment of type II diabetes
  • Developing ERGOSET®
  • Mechanism of action of ERGOSET®
  • Making use of neurotransmitters in regulating metabolism
  • Using their platform technology
  • Gaining market shares within the diabetes market
  • 12:00 CONTRIBUTING TO THE ANTI-DIABETES MARKET

    Dr Roberta L Schneider

    Dr Roberta L Schneider, Vice President, Drug Development and Lead Clinical Researcher, Takeda America R and D Centre

  • Thiazolidinediones: a new class of oral diabetes agents
  • Developing ACTOS™ for the treatment of type II diabetes
  • Mechanism of action of ACTOS™
  • Advantages of ACTOS™
  • Entering into marketing agreements
  • Securing their market position
  • 12:40 Lunch

    14:00 REDUCING THE RISK OF PROGRESSION OF THE MICROVASCULAR COMPLICATIONS OF DIABETES MELLITUS

    Dr Hilary F Marlow

    Dr Hilary F Marlow, Clinical Strategy Leader, Zeneca Pharmaceuticals

  • Zestril™, a leading ACE-inhibitor
  • Providing new indications for Zestril™
  • Bringing real benefits to the patient
  • Reducing healthcare costs
  • Creating awareness; meeting unmet needs
  • Consolidating the presence in diabetes research
  • 14:40 CREATING SOLUTIONS FOR COMPLICATIONS IN DIABETES

    Dr John Egan

    Dr John Egan, Executive Director, Licensing and Technology Development, Alteon

  • Focusing on Advanced Glycosylation End-products (AGEs)
  • AGEs, a causative factor in many complications of diabetes
  • Inhibiting AGE formation / breaking AGE cross-links
  • Pimagedine: benefits of an AGE inhibitor
  • ALT-711, an AGE cross-link breaker for the treatment of cardiovascular diseases in aging and diabetes
  • Developing a novel series of glucose lowering agent compounds
  • 15:20 Afternoon Tea

    15:40 DEVELOPING NOVEL AND SELECTIVE IMMUNOREGULATORY DRUGS

    Dr Louis A Matis

    Dr Louis A Matis, Chief Scientific Officer, Senior Vice President Research, Alexion Pharmaceuticals

  • Research into treatments for insulin-dependent diabetes mellitus
  • Influencing immunoregulatory pathways
  • Developing Apogen DM
  • Mechanism of action of Apogen DM
  • Implications of Apogen DM on the anti diabetics market
  • 16:20 ADVANCING THE TREATMENT OF AUTOIMMUNE DISEASES

    Dr Nanette Solvason

    Dr Nanette Solvason, Scientist, Diabetes Programme, Corixa

  • Building up a strong science platform
  • Developing proprietary biopharmaceutical compounds
  • Selectively interrupting antigen presentation
  • Inactivating T cells mediating the disease process
  • Stepping towards solutions for the treatment of diabetes
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Dr George Morstyn

    Dr George Morstyn, Vice President, Product Development and Chief Medical Officer, Amgen

    9:10 FROM GENE TARGETS TO LEAD IDENTIFICATION

    Dr Maurizio Denaro

    Dr Maurizio Denaro, Executive Vice President, Drug Development, OSI Pharmaceuticals

  • Building a broad pipeline of high quality lead compounds
  • Strategic planning of the drug discovery process
  • Identification of gene targets
  • Using their automated high throughput drug screening for lead identification
  • Using combinatorial chemistry for lead optimisation
  • 9:40 DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE DRUGS IN DIABETES

    Dr Andrés Negro-Vilar

    Dr Andrés Negro-Vilar, Senior Vice President Research and Chief Scientific Officer, Ligand Pharmaceuticals

  • Applying gene transcription technology
  • Using intracellular receptors (IR) technology
  • Employing signal transducers and activators of transcription (STAT)
  • Developing a global pharmaceutical business
  • Focusing on the RXR modulator programme
  • Working on approaches to address diabetes and dislipidemia
  • 10:20 RESEARCH COLLABORATIONS IN THE AREA OF DIABETES

    Thomas A Glaze

    Thomas A Glaze, Chief Executive Officer, Metabolex

  • A disease-focused company addresses diabetes
  • Discovering new therapeutics with a variety of technologies
  • Genomics-based efforts
  • Attacking insulin secretion defects in type II diabetes
  • Counteracting insulin resistance
  • Collaborations with major pharmaceutical companies
  • 11:00 Morning Coffee

    11:20 TRANSLATION OF BASIC RESEARCH FINDINGS INTO CLINICAL REALITY

    Dr Elizabeth D Moyer

    Dr Elizabeth D Moyer, Vice President, Product Development, Kinetek Pharmaceuticals

  • Modulating disease-related signal transduction pathways
  • KP-102: a drug candidate for the treatment of type II diabetes
  • Mechanism of action of KP-102
  • Evaluating the pharmacokinetics, safety and tolerability of KP-102
  • Identifying drug targets using the Kineomics&153; target discovery technology
  • 12:00 MANUFACTURING AND MARKETING INSULIN DELIVERY SYSTEMS

    Terrence H Gregg

    Terrence H Gregg, President and Chief Operating Officer, MiniMed

  • Designing and developing advanced infusion systems
  • The benefit of an implantable insulin pump
  • Developing a glucose sensor
  • Creating an artificial pancreas
  • Benefits for the patient
  • Increasing the profitability by joint research programmes
  • 12:40 Lunch

    14:00 STRATEGIES FOR RAPIDLY GROWING WITHIN THE DIABETES MARKETPLACE

    Dr Christopher Price

    Dr Christopher Price, Chief Executive Officer, Protein Delivery

  • Converting injection-only formulations to oral formulations
  • Status of PDI’s oral insulin clinical studies
  • Medical, patient and economic benefits of oral insulin
  • Application of technology to other therapeutic needs
  • 14:40 NON-INVASIVE DELIVERY OF INSULIN

    Dr Hing Kin Chan

    Dr Hing Kin Chan, Director Business Development, Innovative Dermal Applications

  • Focusing on the non-invasive delivery of peptides and proteins
  • Developing their Transfersomes™ technology
  • Exploring the application of their technology
  • Clinical trials to demonstrate the transdermal delivery of insulin
  • Assessing the commercial potential of their drug delivery technology
  • Strategies for working together with pharmaceutical and biotechnology partners
  • 15:20 Afternoon Tea

    15:40 LONG-TERM DIABETES CARE THROUGH ISLET CELL TRANSPLANT THERAPY

    Dr David Wolf

    Dr David Wolf, Vice President R and D, Biohybrid Technologies

  • Generating and delivering the required amount of insulin through a long-term implant
  • Structure of the implant
  • Mode of action of the implant
  • Benefits for the patient
  • Anticipating the future of cell transplant therapies for the treatment of diabetes
  • Creating their position within the diabetes field
  • 16:20 DEVELOPING NON-INVASIVE MEASUREMENT OF GLUCOSE

    Stephen Malin

    Stephen Malin, President and Chief Executive Officer, Instrumentation Metrics

  • Developing non-destructive analytical measurement instrumentation
  • Applying their technology to non-invasive measurement of glucose in diabetics
  • How does non-invasive measurement of glucose work?
  • Increasing patient’s compliance
  • Pharmacoeconomical implications of non-invasive glucose measurement
  • Strategies for creating their position within the marketplace
  • 17:00 Chairman's Closing Remarks and Close of Conference

    +

    Workshops

    Strategies for Improving the Speed of Clinical Trials
    Workshop

    Strategies for Improving the Speed of Clinical Trials

    The Hatton, at etc. venues
    24th September 1999
    London, United Kingdom

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.